480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this 12-week study was to assess in subjects with chronic hepatitis C
(treatment-naïve, genotype 1) receiving weight-based doses of ribavirin the early virologic
response to the 480 ug dose level of Locteron™, dosed every 2 weeks, in comparison with 1.5
ug/kg PEG-Intron™ dosed weekly.